PHARMA SPACE
Why has Kotak re-initiated inflows into smallcap fund? Harish Bihani explains
There is FOMO in certain sectors and themes across caps and not only in smallcaps. Harish Bihani thinks there is scope for identifying ideas and deploying large sums of money in the smallcap category. The probability of any event specific to India disrupting the market is low at this point and they thought that it was an opportune time to reopen the fund
We continue to remain fully invested; bullish on pharma and IT sector: Vikas Khemani
So, nothing changes from our original hypothesis perspective and we do not churn portfolio very often, so our holding continues to remain more or less same.
What should investors do with HDFC Bank stocks? Rahul Shah answers
So, a good IPO and the way they have priced it also, as you rightly said, that very reasonably priced and some money to be made on the table for the investors and in a pharma pack when we are seeing that most of the pharma packs are doing quite well and the way the segment which has been into Emcure is into, so all the front they have been firing at this point of time.
Stock market update: Nifty Pharma index advances 0.64% in an upbeat market
The Nifty Pharma index was trading 0.64 per cent up at 19913.35.
IPO Analysis: Emcure has better-listed pharma alternatives
Emcure Pharma, with its strong presence in gynaecology and HIV therapeutic areas, secured significant investments from anchor investors like HDFC Mutual Fund and ICICI Prudential Mutual Fund, showcasing immense market confidence in its upcoming IPO.
India best emerging market story; haven't ever seen valuations and fundamentals so attractive: Mihir Vora
The US economy has been much better than expected. It has been stronger for longer and of course, then it also translates to higher interest rates for longer, probably, but the fact is that the US economy is doing quite well.
- Go To Page 1
Like auto & pharma themes? These 2 stocks are your best bet: Rahul Shah
Post their numbers and the management guidance of single-digit growth in the current year, we have seen a decent fall in Sun Pharma. Overall the stock continues to remain strong in the specialty and the overall businesses. The risk versus reward and the valuation remains quite convincing in Sun, says Rahul Shah
Auto stocks: Time for some cool down and also an opportunity? 6 auto stocks with upside potential of upto 28%
It is the sector which has led the rally which the market has witnessed in the last 14 months and rightly so. If one looks at the history, the rallies which are led by the transportation and auto sector are more durable as sales of LCV and certain other auto segments is an indication of the economic situation on the ground. But there is another fact, which is that with a mad rush for stocks a number of them have seen sharp run with valuations moving upward sharply. There is no doubt that the Indian auto sector is going through a transformation and Indian companies are adjusting to it very well. So there is a situation, while the fundamentals are good and improving, valuations have seen a run up. So, there is a likelihood that we might see some cooling off, but that would bring an opportunity for investors who have missed the bus.
2 top stock recommendations from Aditya Arora
I think yes, one should maintain neutral to bullish bias over there and do not go short on the market. A lot of people have a bearish view on the market, but until these levels are not taken out, one should not think of shorting the market.
Outperformance of private sector banks may continue for next one year: Sandip Sabharwal
The smaller pharma companies I find it tough to evaluate, so many of them can potentially do well but I do not have the bandwidth to go molecule by molecule and evaluate those companies. But I think Sun Pharma is a decent business model, so we are just holding it for the long term.
Herd on PE Street: TPG outruns everyone in race for Altimetrik
Last month, its Asia-focused fund TPG Asia VIII secured $5.3 billion in aggregate capital commitments. That made it the firm’s largest Asia fund in 30 years of investing in the region. Since inception, TPG Asia has ploughed more than $13 billion into core sectors including consumer, healthcare, financial services and TMT/new economy and the fund has realised more than $16 billion, according to its website.
Beyond TDP euphoria! Andhra-linked stocks that are worth buying for the long term
Stocks of companies linked to Andhra Pradesh surge post TDP victory, led by Heritage Foods and Aurobindo Pharma.
2 top stock recommendations from Rahul Sharma
And on the upside, structurally, we are seeing this Nifty head towards the 25,000 mark over the next three to six months kind of a timeframe. So, the bull market is very much on. It is just that market is changing gears, especially on the sectoral front. So, one sector that we like particularly is the IT space.
Pankaj Pandey on 4 sectors that may outperform in near term
But our overall sense is that one needs to sort of watch out for Budget plus the element of optimism. Although they have some head room in terms of higher RBI dividend plus, obviously there can be structural savings on the subsidy side especially related to fertilisers, so it remains to be seen how they sort of utilise.
Global PE very active in buying out promoter stakes in listed companies: Gautam Trivedi
But my view is that it is a global product and while we have seen consumption both for defence and railways and infrastructure explode in this country, thanks to the Modi government, I still think that the overall pricing is determined by global factors.So, if prices for steel, for example, were to fall in Shanghai, that impact does come through in our markets as well.
2 top stock recommendations from Soni Patnaik for near term
The first pick would be in the pharma space, we are seeing quite good momentum here today, so pharma you can see Syngene which is giving you a good fresh breakout above 700 level so I think it is looking quite positive from current levels to test higher targets of 720, 725.
2 top stock recommendations from Aditya Agarwala
I think that the euphoria will continue throughout the day and maybe if the results are in line with what we see on the exit polls, the euphoria might continue tomorrow as well. So, today and tomorrow you can see a continuation of this rally that we are seeing in trade today.
As work-from-home trend declines, flexible office spaces work for employees and companies
Providing convenience and flexibility for employees on one hand, cost-effectiveness, and asset-light models for employers on the other, coworking/managed spaces are booming. Demand for such spaces is soaring in large metros and Tier-2 cities alike as companies tighten return-to-office rules.
Book profit in Modi stocks; go for 3 themes that will outperform now: Sanjiv Bhasin
CLSA has labeled certain stocks as 'Modi stocks' which have performed well recently. Sanjiv Bhasin from IIFL Securities suggests booking profits in these stocks, especially PSUs. He recommends focusing on FMCG, private banks, and specialty chemicals for better performance. He also says if one is interested in pharma stocks, it is better to buy a pharma fund.
Nifty may see a 400-point correction before June 4 but banks will outperform: Sanjiv Bhasin
Sanjiv Bhasin from IIFL Securities provides insights on market trends, highlighting the performance of key banks like HDFC, Kotak, ICICI, and Axis. He recommends focusing on IDFC First, Dhanlaxmi Bank, SBI Life, Grasim, LIC, GIC, and New India Assurance for potential growth. Bhasin also says that in pharma, Divi's is one of the best contract pharming companies and it is regaining its position but he would put his money on Lupin.
Pharma an undervalued, under-owned, high on comfort space for next 1-2 years: N Jayakumar
I think the market is not necessarily differentiated between consumption in the rural or consumption in the urban space. I think in general, consumption stocks have been lacklustre, languid if you will, but I think large scale recoveries in the market have happened across the board.
Don't stress on index; take home some money on metals and PSUs before June 4: Sanjiv Bhasin
Sanjiv Bhasin of IIFL Securities believes HDFC Bank will remain a market leader even during a market correction. He suggests taking profits on PSUs before an event as the market is fully priced. Bhasin says one should be stock specific, not place too much stress on the index because we could be headed for a bout of volatility with 500-700 points on the downside.
Expect 15-18% upside in Sun Pharma over medium to long term: Hemang Jani
Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away.
Stay put? Raise cash? What should be your portfolio strategy in runup to the Budget?
Kunj Bansal, NISM, recommends a divided investment approach, focusing on long-term and trading portfolios. He elaborates on portfolio strategies pre-Budget, the pharma sector's defensive appeal, and recent underperformance driving market interest. The IT sectoe has corrected significantly and depending on how things shape up we might see the buying interest coming back.
Mother set of Multibaggers: Evolution of EV ecosystem and emergence of new winners from auto ancillary space
Whether it's institutional or retail investors, the desire to find the next multibagger is always high. But it is not easy to find multibagger stocks for multiple reasons. In the last 30 yearsonly two or three sectors have thrown up multibaggers -- IT, pharma and some engineering or industrial segments. Now the auto and auto ancillary sectors are transforming. From next Sunday onward, we take a deep dive into individual auto ancillary companies which have either transformed due to EV space or are changing themselves or will go down as they are not relevant in new age of EV.
Buy industrials on dips; top 2 bets in two-wheeler space: Deven Choksey
Deven Choksey highlights the importance of market corrections for safe investments. He advises on potential buy opportunities in companies like Tata Technology, Reliance, Tata Power during corrections for better returns.
Stock Radar: Time to buy? Biocon coming out of downward sloping channel; likely to hit fresh 52-week highs
Biocon Ltd, in the pharma sector, witnessed a 40% decline from the December 2020 high but shows signs of a bullish trend. Traders are recommended to consider buying for target levels of 325-350. The daily Relative Strength Index (RSI) is at 65.0. RSI below 30 is oversold and above 70 is considered overbought, Trendlyne data showed.
MrMed ventures into physical retail space with launch of store in Chennai
MrMed is set to inaugurate its inaugural physical store in Greams Road, Chennai on 25 April.
Aditya Arora on where money can be made in pharma space
Aditya Arora of Adlytick maintains a cautious view on the market due to the lack of broad-based rally. Smallcaps are correcting while safe havens like gold and pharma are performing well. Money can be made on the long side of the pharma space and the short side of high beta counters.
Load More
